Patent intelligence · US
US 9567643
Compositions and methods for treating cancers
Compositions and methods for treating cancers
Patent details — US 9567643
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 14, 2017
- Expiration
- Feb 9, 2037
- Applicant
- APTOSE BIOSCIENCES INC.
- Claims
- 12
- CPC classes
- A61K, A61K31/4745, A61K31/706, A61K45/06
Quick answer
US 9567643 (Compositions and methods for treating cancers) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Feb 14, 2017. Expires Feb 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APTOSE BIOSCIENCES INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/4745, A61K31/706, A61K45/06, A61K49/0004, A61P
More from APTOSE BIOSCIENCES INC.
Related pharmaceutical patents in our USPTO index.
-
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
granted -
US 11149047
Aryl imidazoles for treatment of cancer
granted -
US 11104957
Compositions and methods for treating cancers
granted -
US 10080739
Aryl imidazoles and their use as anti-cancer agents
granted -
US 8987305
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
granted -
US 8969372
Aryl imidazoles and their use as anti-cancer agents
granted
Frequently asked questions
What is US patent 9567643?
US 9567643 (Compositions and methods for treating cancers) is held by APTOSE BIOSCIENCES INC.. Status: granted. Granted Feb 14, 2017. Expires Feb 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9567643?
APTOSE BIOSCIENCES INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9567643 expire?
Our index shows an expiration date of Feb 9, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.